Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 Ml;iSpVv[3Srb36gRZN{[Xl? NWLTfHZ5OC53wrFOwG0> M1q5VFI1KGh? M3jzW5difGW{ NHroVWxud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? MY[yOVEzOzB6Mh?=
Eca109 NYX2SVJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz5XWkxNjVxMj61M|Uh|ryP NXrtbG9JOjRxNEivO|IhcA>? NGfMWGN4[XSnch?= Mo\KbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= MVmyOVEzOzB6Mh?=
Eca109 NVjmNnNXTnWwY4Tpc44hSXO|YYm= NInsbFYxNjYEoN88US=> MmDXOk8yOi9{NDDo MoPxe4F1\XJ? NIPWfHNqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg MmXCNlUyOjNyOEK=
Eca109 NETsdItHfW6ldHnvckBCe3OjeR?= M3e4bFAvPcLizszN NHXMZY8zPCCq MkCxe4F1\XJ? NG\p[ppqdmirYnn0d{Bk\WyuIHnueoF{cW:w M{nlflI2OTJ|MEiy
Eca109 NFLvSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWwMlXDqM7:TR?= MoW1NlQhcA>? NXHycFdyf2G2ZYK= MlXObY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> M1L3e|I2OTJ|MEiy
Eca109 MVzGeY5kfGmxbjDBd5NigQ>? NWHUN5A1OC53L{Gg{txO MXOyOEBp NWi3cpR[f2G2ZYK= M1;oe4Rm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? MkXINlUyOjNyOEK=
SW1116  NXy5VnF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOwMlUwOS9{L{Wg{txO M4LoWFQ5KGh? Mn[1SG1UVw>? Mmq3[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> M3PFUVI1QDd2Mki2
LOVO MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PqTlAvPS9zL{KvOUDPxE1? M2XGOVQ5KGh? NVvoeopMTE2VTx?= M2TFUIVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> NUnGSohxOjR6N{SyPFY>
SW1116  MVjGeY5kfGmxbjDBd5NigQ>? NEXrWpQyOCEQvF2= MmTkOFghcA>? NYC2clVDTE2VTx?= NWjjW5N5cW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk M2nQWVI1QDd2Mki2
LOVO NXzWSolGTnWwY4Tpc44hSXO|YYm= M1XVUVExKM7:TR?= MYi0PEBp MWnEUXNQ MWPpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NXvWT5J6OjR6N{SyPFY>
SW1116  NE\6SodCeG:ydH;zbZMhSXO|YYm= NXrGcW41OTBizszN MnfUOFghcA>? NYjt[412TE2VTx?= NEj1bYpmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> M3PDflI1QDd2Mki2
LOVO M{PQNmFxd3C2b4Ppd{BCe3OjeR?= NXrFSZJXOTBizszN NFjwb4Q1QCCq M1XIeGROW09? NFLNPXJmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> MVeyOFg4PDJ6Nh?=
RPMI-8226 NHfiSHZCeG:ydH;zbZMhSXO|YYm= NYXYXJlyOS9{IN88US=> MV:0PE84Oi97NjDo M3;LSWROW09? MlHLbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVOyOFg{OzFyOB?=
OPM-2  MWPBdI9xfG:|aYOgRZN{[Xl? NWT3b3dUOS9{IN88US=> MlL1O|IwQTZxMUKwJIg> NVXDT|h6TE2VTx?= MWfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M2f3T|I1QDN|MUC4
JJN3  MlLBRZBweHSxc3nzJGF{e2G7 NUXTeFdJOC53L{Gg{txO MXKyOE81QCCq NHz0WIdFVVOR NGTi[HBqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVTaSXJGOjR6M{OxNFg>
NCI-H929  NWS5cWlzSXCxcITvd4l{KEG|c3H5 NHnCRpAyNzJizszN M2Ox[FczNzl4L{GyNEBp M{XNeGROW09? MWnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnrHNlQ5OzNzMEi=
RPMI-8226 NGnLPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3aZYgyNzJizszN MXuyOE81QC95MjDo NXH3ZnhmTE2VTx?= M1XNWoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 M{C3[lI1QDN|MUC4
OPM-2  NXHR[Ic4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f1XVEwOiEQvF2= NHPPeXMzPC92OD:3NkBp M3\IPWROW09? NH\0bHFi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MlnCNlQ5OzNzMEi=
JJN3  Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXMNlExNjVxMTFOwG0> MoPtNlQwPDhxN{KgbC=> NITHenVFVVOR MoPrZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NGTSVmgzPDh|M{GwPC=>
NCI-H929  NH7Mb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDoR2IyNzJizszN M2SxV|I1NzR6L{eyJIg> MWjEUXNQ NXPMRoNW[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M3zBSVI1QDN|MUC4
HeLa MV\LbY5ie2ViQYPzZZk> NE\aWmhMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy NELXelczPDd6MEC5PC=>
HeLa M3jGeWtqdmG|ZTDBd5NigQ>? M{juT2tqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> MXKyOFc5ODB7OB?=
HeLa NIjk[opMcW6jc3WgRZN{[Xl? MYDLbV0zOS54INMxJFMvOCEQvF2g[o9zKGiFTmSx MX[yOFc5ODB7OB?=
HeLa NXX6eYZ5U2mwYYPlJGF{e2G7 MUnLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz NXK1NHV[OjR5OECwPVg>
NB4 MkjTSpVv[3Srb36gRZN{[Xl? NVTFS5h4Oi53L{WvO{42NzFyIN88US=> MoHRNlQhcA>? Mo\HSG1UVw>? M3v1W4lv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE> NXzGdHF4OjR2OES4O|A>
CD4+ CD25− T  NGPaNo5HfW6ldHnvckBCe3OjeR?= NXzJe5B3OS93IN88US=> M1LlVpJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NWWxbJhFOjR2N{[zOlA>
BV-173 Mk\4RZBweHSxc3nzJGF{e2G7 NVHISll1OC5{NT:wMlUwOC55NT:xJO69VQ>? MlP3OFgwPzJxOU[gbC=> MUVCpHBDWw>? MkPpbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NGfCeVczPDR{M{[xNy=>
ML-1 MVXBdI9xfG:|aYOgRZN{[Xl? MkDFNE4zPS9yLkWvNE44PS9zIN88US=> MXq0PE84Oi97NjDo MXRCpHBDWw>? MkS5bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M2n2e|I1PDJ|NkGz
HL-60 MVXBdI9xfG:|aYOgRZN{[Xl? MlG1NE4zPS9yLkWvNE44PS9zIN88US=> MYq0PE84Oi97NjDo MVNCpHBDWw>? MkfHbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M1PtdlI1PDJ|NkGz
KG-1a Mlm4RZBweHSxc3nzJGF{e2G7 NXjmZVBQOC5{NT:wMlUwOC55NT:xJO69VQ>? NVP0XIxbPDhxN{KvPVYhcA>? NF\FXonDqFCEUx?= MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MlzCNlQ1OjN4MUO=
BV-173 NVrTell7TnWwY4Tpc44hSXO|YYm= MX[yOVAwPTBybl2= M3jvWVQ5KGh? M3jWZuKhWEKV MVPpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NVfRcZFnOjR2MkO2NVM>
CEM MYrGeY5kfGmxbjDBd5NigQ>? Mmi2NlUxNzVyMH7N MUW0PEBp NEnsVI/DqFCEUx?= NYnsPY4xcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MnTGNlQ1OjN4MUO=
HL-60 NGfEcWRHfW6ldHnvckBCe3OjeR?= Mnz0NlUxNzVyMH7N MXq0PEBp NELucnnDqFCEUx?= MmTNbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NWK3VHpjOjR2MkO2NVM>
ML-1 NVmyZm5iTnWwY4Tpc44hSXO|YYm= M4\Je|I2OC93MEDuUS=> NWDZc4F{PDhiaB?= MUJCpHBDWw>? MlGxbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M3jkRlI1PDJ|NkGz
DLD-1 NFfU[WJHfW6ldHnvckBCe3OjeR?= NWK4elNKOjVyL{WwNI5O NFfVPVY1QCCq MUVCpHBDWw>? MWHkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NYT3W4x6OjR2MkO2NVM>
HCT-116 MUjGeY5kfGmxbjDBd5NigQ>? MWmyOVAwPTBybl2= NYm5V4pYPDhiaB?= NWKyO5N[yqCSQmO= NXW1ZWl7\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NXPHblVLOjR2MkO2NVM>
U937-A/E-9/14/18  MX;BdI9xfG:|aYOgRZN{[Xl? NEXsRlMxNjBzL{CuNU8yNzFyIN88US=> MmGxOFghcA>? MmrQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYn1O49zOjR|MEC0OVY>
HT29 M17Xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[4cG9NPzJiaB?= M4OwTWlEPTB;MUSwNOKyOTd7IN88US=> M3LmSVI1OTd{ME[x
SW48 M3O1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX75[mxZPzJiaB?= NEWxU2pKSzVyPUG1MlLDuTZwMjFOwG0> MofLNlQyPzJyNkG=
HCT116 NW\tdFBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7L[4pMPzJiaB?= M4HQdGlEPTB;MT63xtExNjRizszN M2XzblI1OTd{ME[x
HepG2 MorKSpVv[3Srb36gRZN{[Xl? NXzqNnpPOC53L{Gg{txO NVLlfnM5OjRiaB?= MnXxSG1UVw>? Mmi2eZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M3e5TFI1OTR4OEe0
LS174T NX3GZnhlTnWwY4Tpc44hSXO|YYm= M2\lO|AvPS9zIN88US=> MorBNlQhcA>? M3qzN2ROW09? NVfiUolxdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> MXOyOFE1Pjh5NB?=
HepG2 MXrBdI9xfG:|aYOgRZN{[Xl? NGjFbFkyNzFyL{GwNEDPxE1? NUHHW2VSPyCm NF;1WGtFVVOR MoTzbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYOyOFE1Pjh5NB?=
LS174T NGnTdW1CeG:ydH;zbZMhSXO|YYm= MWmxM|ExNzFyMDFOwG0> NXHXPVJDPyCm M1T6ZWROW09? M2rSRYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV[yOFE1Pjh5NB?=
QBC-939 MnjXRZBweHSxc3nzJGF{e2G7 MY[xM|ExNzFyMDFOwG0> NIfPb|Y4KGR? MmPtSG1UVw>? NEGyd4FqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVWyOFE1Pjh5NB?=
U251 NHflWZNCeG:ydH;zbZMhSXO|YYm= NHn4fWUyNzFyL{GwNEDPxE1? MXy3JIQ> NX62SXdPTE2VTx?= M4rjdIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGLmeoIzPDF2Nki3OC=>
HL-60 NUfpdmVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P4clEh|ryP NXzyW3NbPDhiaB?= MkTPbY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? M4nnVFI1ODByM{K0
MDA‑MB‑453 M2PUPWZ2dmO2aX;uJGF{e2G7 NVLMPHJIOC5{L{Gg{txO MU[3NkBp M4TZO4NifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NIK5d2szOzh2NEKyPC=>
HCC1569 NUPYOJdKTnWwY4Tpc44hSXO|YYm= MkG5NE4zNzFizszN MVW3NkBp M1;GXYNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> M17Nc|I{QDR2MkK4
BT‑474 NEjZTZhHfW6ldHnvckBCe3OjeR?= MYGwMlIwOSEQvF2= NGq1Xmk4OiCq NYXwbm03[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh M2rq[|I{QDR2MkK4
AGS NYfTWpV3SXCxcITvd4l{KEG|c3H5 NWXhTpRuPS9zMD:yNE82OCEQvF2= NEfOZoU1QMLiaNMg M1fM[GROW09? MlPQbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MofZNlM2QDJ5OES=
A549 MlfKRZBweHSxc3nzJGF{e2G7 M{XQZlUwOTBxMkCvOVAh|ryP NILTV4E1QMLiaNMg MnXmSG1UVw>? MlHWbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MlrnNlM2QDJ5OES=
AGS  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHkOU8yOC9{MD:1NEDPxE1? NUXaPXBzPDkEoHlCpC=> M{fpXmROW09? M1e3Solv\HWlZYOgS|IwVSCyaHHz[UBienKnc4VCpC=> NYTrSZhnOjN3OEK3PFQ>
Kasumi-1 M3yye2Fxd3C2b4Ppd{BCe3OjeR?= NU\KSJE5OC53IN88US=> M2LEZlQ5yqCqwrC= NXvNRWVW\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> M2DFfVI{PDl|M{S4
OCI-AML3 MWfBdI9xfG:|aYOgRZN{[Xl? NFr6SlIzNjVizszN MYe0POKhcMLi MkP6[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MUmyN|Q6OzN2OB?=
MV4-11 MlztRZBweHSxc3nzJGF{e2G7 MYGyMlUh|ryP MVq0POKhcMLi NWHYbFcx\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MojMNlM1QTN|NEi=
NK  NV;hdJdkS3m2b4TvfIl1gSCDc4PhfS=> NGfvTWcxNjB{LUKwJO69VQ>? NYPLWpBqPSCm NWG4XWRz\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= NFv4NIMzOzN{OEC4PC=>
NK  NUj5WpNMSXCxcITvd4l{KEG|c3H5 NF:wWXYxNjB{LUKwJO69VQ>? M1P4PVUh\A>? MmGw[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MV2yN|MzQDB6OB?=
NK  MWrGeY5kfGmxbjDBd5NigQ>? MWGwMlAyNTJyIN88US=> MWq1JIQ> NYLyOmNw[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? NYDjZ3VWOjN|MkiwPFg>
MOLT4/DNR NGDi[HNHfW6ldHnvckBCe3OjeR?= NHy0SIw2KM7:TR?= MoOyOEBl MVXy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NIDQeJMzOzB4MEW3NC=>
Jurkat/DOX M3vvW2Z2dmO2aX;uJGF{e2G7 M{\rN|Uh|ryP Mn3kOEBl M2jldZJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v M1rBUlI{ODZyNUew
MOLT4/DNR NXfDdGZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWyNoE2KM7:TR?= MXK0JIQ> NHjo[4lz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 NWq0b3ZDOjNyNkC1O|A>
Jurkat/DOX NX7kW2FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID4VG02KM7:TR?= MkX2OEBl M2e0XpJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= MWqyN|A3ODV5MB?=
ccRCC  M2ju[GFxd3C2b4Ppd{BCe3OjeR?= NV3wT452OC5yMT2xNO69VQ>? NE[4[m44OiCq MUDEUXNQ NELDZ5Vp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w MXqyNlgzPjR4Nx?=
TNBC  NUixdFhqSXCxcITvd4l{KEG|c3H5 MUiwMlAyNTFyzszN MofKO|IhcA>? NFHiU3ZFVVOR MXnoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MXeyNlgzPjR4Nx?=
A498 NUfNWFJ[SXCxcITvd4l{KEG|c3H5 MmfHNE4xOS1zMN88US=> MXm3NkBp Mm\oSG1UVw>? MnPYbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NVTmUJV1OjJ6Mk[0Olc>
KIJ265T NVv5U4xLSXCxcITvd4l{KEG|c3H5 MViwMlAyNTFyzszN M4m1U|czKGh? MoPqSG1UVw>? M2PkOIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NVPCenZ{OjJ6Mk[0Olc>
MDA-231 MVHBdI9xfG:|aYOgRZN{[Xl? MXiwMlAyNTFyzszN NH7iRZc4OiCq NEPDbm9FVVOR Mnj3bY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MkmyNlI5OjZ2Nke=
BT-20 NVjRUodQSXCxcITvd4l{KEG|c3H5 M13B[|AvODFvMUFOwG0> MnzEO|IhcA>? NEXTTJdFVVOR NVPMd5VTcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NHizVIYzOjh{NkS2Oy=>
U937 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonCOU0zOCEQvF2= MYmyOE81QC95MjDo Moi4bY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NF;UdmMzOjd4N{CyNS=>
HL60 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW1MVIxKM7:TR?= NGTnW2MzPC92OD:3NkBp NHq4VYNqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz M{nVZlIzPzZ5MEKx
U937 MW\BdI9xfG:|aYOgRZN{[Xl? M2\0UVE2KM7:TR?= MXuyOE81QC95MjDo NXe2NFhJcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXPQbFdROjJ5NkewNlE>
HL60 M3jpfWFxd3C2b4Ppd{BCe3OjeR?= M336c|E2KM7:TR?= M4TUOFI1NzR6L{eyJIg> M4rnS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGfmVJUzOjd4N{CyNS=>
LS411N  NFvKN2FCeG:ydH;zbZMhSXO|YYm= NFG0UHAxNjVizszN MWW3NkBp NWX5NIhVcW6lcnXhd4V{KE[jczDtVm5CKGyndnXs M33nRlIzPDZzNkm1
MDA-MB-231 MXHBdI9xfG:|aYOgRZN{[Xl? NI\JO3kyOCEQvF2= NV;mdHg{PDhiaB?= NHTvcmtz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{CwNVIyQDh5Nkm3
MCF-7  M2fhbmFxd3C2b4Ppd{BCe3OjeR?= M3zNOFExKM7:TR?= NIXvOJQ1QCCq NXT6NmNxemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1XLNVIyQDh5Nkm3
A375 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rLV|AvPSEQvF2= MWGxM|UwQCCm MYLpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NGjlfm0zOTd7Nk[yNi=>
SKMEL1 NGfKfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;6V2kxNjVizszN NWDpXHNIOS93L{ig[C=> NVPvc4V2cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MWGyNVc6PjZ{Mh?=
SKMEL3 NU[wNm8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\xNZAxNjVizszN NV\CSWhnOS93L{ig[C=> NH76TGxqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M4jYdlIyPzl4NkKy
SKMEL28 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\xNE42KM7:TR?= MXixM|UwQCCm NF7XVm5qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M13v[|IyPzl4NkKy
MeWo MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD2V|hpOC53IN88US=> MU[xM|UwQCCm NWfUfHp[cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M2roWlIyPzl4NkKy
B16 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\melNvOC53IN88US=> Mmf6NU82NzhiZB?= M1\YbYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MW[yNVc6PjZ{Mh?=
Ly 1 NFzU[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XVR|I1KGh? M3fMcmlEPTB;Nz6zJO69VQ>? MXSyNVc4OjB2OR?=
Ly 7 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPDO5ozPCCq NIizfJJKSzVyPUGwMlch|ryP NUTp[4w1OjF5N{KwOFk>
Su-DHL6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS3cW1OOjRiaB?= NFLu[Y5KSzVy78{eNlAh|ryP Ml7vNlE4PzJyNEm=
Ly 10 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO0NXlwOjRiaB?= M{\zOGlEPTExvK6yNEDPxE1? MWqyNVc4OjB2OR?=
RIVA M4jWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n5PVI1KGh? M37QV2lEPTExvK6yNEDPxE1? MUmyNVc4OjB2OR?=
Su-DHL2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInsXlUzPCCq Mnn6TWM2OO,:nkKwJO69VQ>? NYrhNlhkOjF5N{KwOFk>
Ly 1 NHLDZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXS0PEBp MWDJR|UxRTBwM{Sg{txO M2jBc|IyPzd{MES5
Ly 7 NUPoeotoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3m[241QCCq MnzJTWM2OD1yLkCyOUDPxE1? M3zw[FIyPzd{MES5
Su-DHL6 M3XXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWi0PEBp MmDiTWM2OO,:nkKwJO69VQ>? M1\MWlIyPzd{MES5
Ly 10 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi0PEBp NXPHT4hjUUN3ME2xMlgh|ryP NEn3N4ozOTd5MkC0PS=>
RIVA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPFR4g1QCCq M1XDTmlEPTExvK6yNEDPxE1? M3XYUVIyPzd{MES5
Su-DHL2 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKyWHA4PDhiaB?= Ml7PTWM2OD1zNz60JO69VQ>? M4XIPFIyPzd{MES5
Ly 1 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVO3NkBp M3TzUmlEPTB;MD6wNUDPxE1? NVr2XWRZOjF5N{KwOFk>
Ly 7 NHvLbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfvO|IhcA>? NEn5[2ZKSzVyPUCuNFE5KM7:TR?= MoDwNlE4PzJyNEm=
Su-DHL6 M3vCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWi3NkBp MmH0TWM2OD1zLk[g{txO NVrCXZlnOjF5N{KwOFk>
Ly 10 NVWxPZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK0cIo4OiCq NETO[ZVKSzVyPUGuNkDPxE1? MlfXNlE4PzJyNEm=
RIVA MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1eyVlczKGh? MVPJR|Ux97zgMkCg{txO NEfofVYzOTd5MkC0PS=>
Su-DHL2 NHTpPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33acVczKGh? NVq3[plFUUN3ME2xNU4zKM7:TR?= MU[yNVc4OjB2OR?=

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID